Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

But employers and unions will ultimately determine how much of those savings on Wegovy get shared with members, CVS said ... the weight loss drug market and concerns that Zepbound's sales ...